Table 3.
Risk of aggressiveness clinicopathological features in patients with papillary thyroid cancer according to BMI group.
| BMI at diagnosis (kg/m2) | ||||
|---|---|---|---|---|
| BMI < 18.5 N = 78 |
18.5 ≤ BMI < 23 N = 826 |
23 ≤ BMI < 27.5 N = 414 |
BMI ≥ 27.5 N = 304 |
|
| Primary tumor size ≥1 cm | ||||
| Number of patients (%) | 30 (38.46%) | 340 (41.16%) | 147 (35.5%) | 148 (48.68%) |
| OR (95% CI) | 0.90 (0.56–1.44) | Reference | 0.79 (0.59–1.06) | 1.33 (0.90–1.98) |
| p value | 0.37 | 0.07 | 0.10 | |
| Extrathyroidal extension | ||||
| Number of patients (%) | 27 (34.62%) | 287 (34.75%) | 170 (41.06%) | 141 (46.38%) |
| OR (95% CI) | 0.99 (0.61–1.60) | Reference | 1.32 (0.98–1.76) | 1.61 (1.08–2.4) |
| p value | 0.54 | 0.04 | 0.01 | |
| Multifocality | ||||
| Number of patients (%) | 24 (30.77%) | 263 (31.84%) | 167 (40.34%) | 129 (42.43%) |
| OR (95% CI) | 0.95 (0.58–1.56) | Reference | 1.45 (1.08–1.94) | 1.58 (1.05–2.36) |
| p value | 0.48 | 0.009 | 0.02 | |
| Cervical lymph node metastasis | ||||
| Number of patients (%) | 28 (35.9%) | 314 (38.01%) | 163 (39.37%) | 149 (49.01%) |
| OR (95% CI) | 0.91 (0.57–1.47) | Reference | 1.06 (0.79–1.42) | 1.57 (1.06–2.34) |
| p value | 0.40 | 0.37 | 0.02 | |
| Distant metastasis | ||||
| Number of patients (%) | 3 (3.85%) | 14 (1.69%) | 11 (2.68%) | 2 (1.89%) |
| OR (95% CI) | 2.27 (0.66–7.79) | Reference | 1.57 (0.63–3.94) | 1.09 (0.25–4.73) |
| p value | 0.17 | 0.23 | 0.57 | |
| Advanced TNM stage | ||||
| Number of patients (%) | 29 (37.18%) | 301 (36.44%) | 189 (45.65%) | 154 (50.66%) |
| OR (95% CI) | 1.03 (0.64–1.66) | Reference | 1.47 (1.10–1.96) | 1.81 (1.23–2.70) |
| p value | 0.50 | 0.006 | 0.002 | |